Cyclooxygenase-2 protein reduces tamoxifen and N-(4-hydroxyphenyl)retinamide inhibitory effects in breast cancer cells (Q40380549)

20 September 2017

title

Cyclooxygenase-2 protein reduces tamoxifen and N-(4-hydroxyphenyl)retinamide inhibitory effects in breast cancer cells (English)

1 reference

20 September 2017

1 reference

Ana M Tari

1

1 reference

20 September 2017

Ann-Marie Simeone

2

1 reference

20 September 2017

Yu-Jiang Li

3

1 reference

20 September 2017

Yolanda Gutierrez-Puente

4

1 reference

20 September 2017

Syeling Lai

5

1 reference

20 September 2017

William F Symmans

6

1 reference

20 September 2017

publication date

1 November 2005

1 reference

20 September 2017

published in

Laboratory Investigation

1 reference

20 September 2017

volume

85

1 reference

20 September 2017

issue

11

1 reference

20 September 2017

page(s)

1357-1367

1 reference

COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700339

Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700339

Prostaglandins and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700339

Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700339

Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700339

Cyclooxygenase-2 is essential for HER2/neu to suppress N- (4-hydroxyphenyl)retinamide apoptotic effects in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700339

Mechanisms of tamoxifen-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700339

Downregulation of Wilms' tumor 1 protein inhibits breast cancer proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700339

N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700339

4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700339

HER2/neu reduces the apoptotic effects of N-(4-hydroxyphenyl)retinamide (4-HPR) in breast cancer cells by decreasing nitric oxide production

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700339

Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700339

Differential SERM effects on corepressor binding dictate ERalpha activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700339

Molecular determinants for the tissue specificity of SERMs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700339

Molecular basis of agonism and antagonism in the oestrogen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700339

The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700339

Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700339

Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700339

Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700339

Elevated protein kinase C alpha expression may be predictive of tamoxifen treatment failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700339

Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700339

Cyclic AMP binding proteins and prognosis in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700339

Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700339

Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700339

inferred from DOI database lookup

7 January 2021

based on heuristic

N-(4-Hydroxyphenyl)retinamide Activation of a Distinct Pathway Signaling Apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700339

inferred from DOI database lookup

7 January 2021

based on heuristic

Tumour cyclic AMP binding proteins: an independent prognostic factor for disease recurrence and survival in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700339

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LABINVEST.3700339

1 reference

20 September 2017

1 reference